To determine the incidence of elevated levels of serum methylmalonic acid in patients with cobalamin deficiency, we utilized a new capillary gas chromatographic-mass spectrometric technique to measure methylmalonic acid in the serum of 73 patients with clinically confirmed cobalamin deficiency. Values ranged from 55 to 22,300 ng/ml, and 69 of the 73 patients had values above the normal range of 19-76 ng/ml as determined for 50 normal blood donors. In the cobalamin-deficient patients, serum methylmalonic acid was significantly correlated with the serum folate level and the degree of neurologic involvement. Some patients with pernicious anemia who were intermittently treated with cyanocobalamin were found to have elevated serum levels of methylmalonic acid while free of hematologic and neurologic abnormalities. A cobalamin-deficient patient is described with a normal serum cobalamin and an elevated serum methylmalonic acid. We conclude that the ability to measure methylmalonic acid in human serum will be useful in studies designed to determine the incidence of cobalamin deficiency in various patient populations.
Introduction
Previous investigators have shown that most patients with cobalamin (Cbl, vitamin B12)' deficiency have elevated levels of methylmalonic acid in their urine (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . The origin of the methylmalonic acid has recently been elucidated (13) and is illustrated in Fig. 1 . In Cbl deficiency, reduced levels ofadenosylCbl result in decreased activity of L-methylmalonyl-coenzyme A (CoA) mutase and a resultant increase in intracellular levels ofL-methylmalonyl-CoA. D-methylmalonyl-CoA is also elevated due to the activity of D,L-methylmalonyl-CoA racemase (14) and is cleaved to coenzyme A and methylmalonic acid by the recently recognized and characterized enzyme, D-methylmalonyl-CoA hydrolase (13) . Methylmalonic acid is then released into blood in unknown amounts and is excreted in the urine. In normal individuals (15) and laboratory animals (13), about 1 . Abbreviations used in this paper: Cbl, cobalamin; CN-Cbl, cyano-Cbl; CoA, coenzyme A; MCV, mean corpuscular volume; LDH, lactate dehydrogenase.
70% ofmethylmalonic acid in blood is metabolized to unknown products via undefined pathways and only about 30% is excreted in the urine.
At the present time, the serum Cbl assay is essentially the only laboratory test generally available for use in determining if a patient is Cbl-deficient, and this limitation has been widely recognized (16) (17) (18) (19) . Low serum Cbl values in patients without hematologic abnormalities are frequently encountered in screening studies (16) (17) (18) (19) , in the elderly (20, 21) , and in patients with certain neuropsychiatric abnormalities (22, 23) , but their significance has been difficult, if not impossible, to determine. More rarely, diagnostic problems can also develop in patients with hematologic abnormalities, since serum Cbl levels may be normal in Cbl-deficient patients who have elevated levels ofCblbinding proteins (24) . Additional diagnostic tests like urinary methylmalonic acid (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) and the deoxyuridine suppression test (25, 26) have not been widely used and, thus, a definite need exists for additional tests that could be used to evaluate patients for Cbl deficiency and to evaluate the sensitivity and specificity of the serum Cbl assay.
We have recently developed a new capillary gas chromatography-mass spectrometry method that is capable of detecting and quantitating methylmalonic acid in normal human serum (15) . We now report the use of this method to measure methylmalonic acid in the serum of patients with clinically confirmed Cbl deficiency.
Methods
Assay ofmethylmalonic acid and succinic acid. Methylmalonic acid and succinic acid were assayed using capillary gas chromatography-mass spectrometry as previously described in detail (15) . Briefly, 50 ll of H20 containing 200 ng of[methyl-2H3]methylmalonic acid (>99%) and 2,000 ng of [1, acid (>99%) is added to 50-500 M1 of human serum and the total volume, ifneeded, is brought up to 550 Ml with H20. The samples are then extracted with ether, partially purified by high performance liquid chromatography using an anion exchange resin at pH 2, repeat ether extraction, formation of the t-butyldimethylsilyl derivatives using N-methyl-N(t-butyldimethylsilyl)trifluoroacetamide, extraction of the derivatives into hexane, and volume reduction using a stream of nitrogen. The samples are analyzed on a Durabond DB-5 fused silica capillary column (30 m X 0.25 mm i.d., 0.25 gm film thickness) from J & W Scientific, Inc. (Rancho Cordova, CA) and a HewlettPackard Co. (Palo Alto, CA) 5992B gas chromatography-mass spectrometer equipped with a falling-needle injector. Quantitation is based on the ratio ofthe areas ofthe base peak ion 289.2 for the methylmalonic acid and succinic acid derivatives, which elute at different times, to the areas ofthe base peak ions of 292.2 and 291.2 for the derivatives oftheir respective stable isotope internal standards. Methylmalonic acid and succinic acid are very stable in collected serum, as no change or trend in values for these two dicarboxylic acids was noted in a sample ofpooled normal human serum that was frozen, thawed, and assayed 17 different times over a 10-mo period (15) . Values for serum methylmalonic acid of serum methylmalonic acid is excreted in the urine and 70% is metabolized to unknown products via undefined pathways (13) .
fuged at 40C were the same as those obtained with portions of the same blood samples that were incubated at room temperature for 1-24 h before centrifugation (15) . Values for serum succinic acid increased about 90% over the 24-h time period (15 Subjects andpatients. Serum samples from 50 normal blood donors, 25 males and 25 females, ranging in age from 18 to 65 yr were obtained as described previously (15 Cbl levels were assayed using the Lactobacillus leichmannii method or a number of radiodilution assays utilizing purified intrinsic factor or gastric juice with more than 95% ofCbl binding activity due to intrinsic factor. Serum folate was assayed with the Lactobacillus casei method or by milk binder radiodilution assay. All of the patients' samples were coded in a manner such that the categories to which they belonged and the number ofpatients in each category were not known by the personnel involved in performing the methylmalonic acid and succinic acid assays, until after the results were reported to Dr. Lindenbaum. Statistical methods. A number offactors were examined individually for possible relationships with serum methylmalonic acid and succinic acid. For factors that were discrete, such as sex, race, and diagnosis, the Wilcoxon two-sample test was used to determine the significance of the relation. For assessing possible relationships with neurologic severity, groups 0, 1, and 2 (as defined in Table I ) were combined and compared with combined groups 3 and 4. Factors that were continuous, such as age or mean corpuscular volume (MCV), were examined using Spearman correlation coefficients.
Results
The values obtained for serum methylmalonic acid and succinic acid for the normal subjects and patients in the various categories are shown in Fig. 2 . In the Cbl-deficient group, 69 of the 73 patients had values for methylmalonic acid that were above the normal range of 19-76 ng/ml. The highest value was 22,300 ng/ ml and the median value was 1,100 ng/ml. 5 of the 16 folatedeficient patients had mild elevations of serum methylmalonic acid with the highest value being 140 ng/ml. 7 of 15 samples from the Cbl-deficient infrequently treated patients who lacked hematologic and neurologic abnormalities had elevated values that ranged as high as 175 ng/ml. Of these seven samples, serum L. leichmannii Cbl concentrations were low (88-165 pg/ml) in six and normal (275 pg/ml) in one. All seven samples gave low Cbl values (85-155 pg/ml) with radiodilution assay using purified intrinsic factor. Ofthe eight samples with normal levels ofmethylmalonic acid, serum L. leichmannii Cbl was low in four.
Elevated values for serum succinic acid were observed in 19 of the 73 Cbl-deficient patients, 10 of the 16 folate-deficient patients, and 8 of the 15 Cbl-deficient infrequently treated patients. The reason for these elevations is unknown, but could be related to variations in the time that blood is allowed to stand before the serum is separated, since we have found (15) that values for serum succinic acid may double when blood is allowed to stand for 24 h at room temperature before centrifugation. Values for serum methylmalonic acid do not change over this time period (15) .
Clinical data concerning the 73 patients with Cbl deficiency are presented in Table I where they are arranged in decreasing order with respect to their serum methylmalonic acid levels. There was a significant correlation between serum methylmalonic acid and serum folate (r = 0.45; P < 0.001). The correlation was present in samples measured by the L. casei serum folate method (r = 0.46; P < 0.01) as well as the radioassay technique (r = 0.66; P < 0.001). Patients with more severe neurologic abnormalities (groups 3 and 4) had higher serum methylmalonic acid levels (mean±SD, 5077±6073, median 3685 ng/ml) than those with milder abnormalities (groups 1 and 2, mean 2083±2866, median 879 ng/ml) or no evidence of neurological involvement (group 0, mean 1154±1468, median 409 ng/ml) (P < 0.01 for groups 3 and 4 vs. 0-2).
Serum Cu 00 C-00 -< < g < g g g < < g < < < < < g co rA < (05 < g < Figure 2 . Levels of serum methylmalonic acid (bottom) and serum succinic acid (top) in patients with clinically confirmed Cbl deficiency, folate deficiency, and Cbl-deficient infrequently treated patients who had no hematologic or neurologic abnormalities using capillary gas chromatography-mass spectrometry. The normal range for methylmalonic acid is 19-76 ng/ml, and 580-2420 ng/ml for succinic acid.
t X t t t t t t t tt E t t t t< E 0 t t t E a t i t
These ranges were calculated as the mean±2 SD after log transformation to correct for skewness towards higher values.
vs. folate in patients without neurologic disorders, 0.58; n = 27; P < 0.01). Although serum folate concentrations were higher in patients with more severe neurological abnormalities (mean serum folate in groups 3 and 4, 20.9±16.9 vs. 10.1±8.7 ng/ml in groups 0-2, P < 0.005), the association ofhigher serum methylmalonic acid levels with advanced neurological involvement appeared to be independent of folate status. In patients with serum folate levels below 15 ng/ml, mean serum methylmalonic acid in groups 3 and 4 was 3189±2317 ng/ml vs. 1030±1795 ng/ml in groups 0-2 (P < 0.005); serum folates did not differ significantly between the two subgroups (7.5±3.3 vs. 6.0±3.8 ng/ml, respectively, P > 0.25).
There was a negative correlation between the platelet count and serum methylmalonic acid levels (r =-0.30; P < 0.05). However, the correlation was no longer significant if patients with more severe neurologic abnormalities (groups 3 and 4) were omitted from the analysis (r = -0.26; P > 0.05) or if patients with elevated serum folates were omitted (r = -0.23; P > 0.05). Patients with pernicious anemia had higher values for serum methylmalonic acid (mean, 2968±4387 ng/ml) than those with tropical sprue (714±1007, P < 0.004 using Mann-Whitney test); when corrected for the generally lower serum folate values and less severe neurologic involvement in the patients with tropical sprue, however, the difference was no longer significant. Patients with glossitis had higher serum methylmalonic acid values than patients without tongue signs or symptoms; however, 13 of the 16 patients with glossitis with serum levels of methylmalonic acid above the median for the entire group of 73 patients had severe neurologic involvement, elevated serum folate values, or both.
Serum methylmalonic acid was not correlated with serum Cbl (r = -0.09 for all patients; r = 0.12 for microbiologic assay;
and -0.09 for radioassays, P > 0.4 in each instance). Serum methylmalonic acid was not significantly correlated with MCV (r = 0.07, P > 0.05), white blood cells (r =-0.08; P > 0.3), or hematocrit (r =-0.12; P > 0.4). All of the 12 patients with normal hematocrits had elevated serum methylmalonic acid levels (range 1 16-4800 ng/ml). There was no correlation between serum methylmalonic acid and age, sex, race, duration of symptoms, extent of weight loss, or serum levels of iron, lactate dehydrogenase (LDH), bilirubin, or albumin. Four patients with untreated Cbl deficiency (Nos. 70-73, Table I ) had serum methylmalonic acid levels within the normal range. Three had tropical sprue. One of the four had impaired proprioception and vibration sense without neurological symptoms. There were no clinical or laboratory features that differentiated these patients from those with elevated serum methylmalonic acid concentrations.
Values for serum succinic acid did not correlate with any of the parameters studied, including serum methylmalonic acid, and significant differences were not observed between any ofthe various subgroups. Fig. 3 shows sequential levels of serum and urine methylmalonic acid in a patient with classic pernicious anemia, beginning at the time of diagnosis and continuing over the first 13 d after treatment with parenteral Cbl. Both values were markedly elevated before treatment, both decreased at similar rates after treatment, and both were just above the upper limit of normal on day 13 . This suggests that measurements of serum and urine methylmalonic acid would correlate well with one another as diagnostic tests for Cbl deficiency, but a large number of additional patients must be studied before this can be concluded with certainty. Table II contains Figure 3 . Levels of serum ( * ) and urine (----) methylmalonic acid in a patient with pernicious anemia before and after treatment with cyano (CN)-Cbl using capillary gas chromatography-mass spectrometry. The patient was a 32-yr-old white male with pancytopenia, megaloblastic bone marrow findings, a serum Cbl value of 43 pg/ml, serum anti-intrinsic factor-blocking antibodies, and an abnormal Schilling test that corrected with exogenous intrinsic factor.
1610 S. Stabler, P. Marcel, E. Podell, R. Allen, and J. Lindenbaum (27, 28) . It is possible that in folate deficiency an attempt is made to increase levels of methionine synthetase activity by increasing the amount of Cbl bound to methionine synthetase with the result that the amount of Cbl bound to L-methylmalonyl-CoA mutase is decreased, and that this in turn results in increased formation of methylmalonic acid (see Fig. 1 ).
Levels ofserum methylmalonic acid were not correlated with levels of serum Cbl in the Cbl-deficient patient group. A correlation between Cbl levels and levels of urinary methylmalonic acid was observed previously in some studies (3, 5) but not in others (1, 8, 9) . The failure to find correlations between serum methylmalonic acid levels and any of the hematologic parameters, except for a weak inverse correlation with platelet count, is in agreement with studies employing levels of urinary methylmalonic acid (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Previous workers, studying small numbers of patients with neurologic abnormalities, have found no correlation with urine levels of methylmalonic acid (3, 4, 8, 9) or have suggested a possible relationship (2, (10) (11) (12) . The positive correlation between serum methylmalonic acid levels and the presence of neurologic abnormalities in our large series of patients is of interest, since the biochemical mechanisms responsible for the neurologic abnormalities in Cbl deficiency are still unknown. The positive correlation between serum folate levels and serum methylmalonic acid levels has also not been noted in studies of urinary methylmalonic acid levels (1) (2) (3) (4) (5) (6) (7) (8) (9) . This correlation could be due to the fact that patients on diets with relatively high folate contents might have fewer hematologic abnormalities, possibly resulting in a delay in the diagnosis of Cbl deficiency. The fact that values for serum folate were not positively correlated with any hematologic parameter makes this unlikely, however. It is also possible that some unknown metabolic or regulatory relationship exists between L-methylmalonyl-CoA mutase and methionine synthetase in addition to the fact that they both require Cbl for activity.
